Evaluating hydronidone for the treatment of chronic hepatitis B-associated liver fibrosis

Evaluating hydronidone for the treatment of chronic hepatitis B-associated liver fibrosis

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs specifically designed to treat liver fibrosis.

Anticipated Phase 3 Trial of Hydronidone for Treating Liver Fibrosis in Chronic Hepatitis B

With valid phase 2 results, hydronidone could pave the way for first antifibrotic treatment in chronic liver disease.

HIF-1α/LTBP2 Axis Activate HSCs to Promote Liver Fibrosis by Interacting with LOXL1 via the ERK Pathway

The authors elucidated the function and mechanism of latent transforming growth factor beta binding protein 2 (LTBP2) in hepatic stellate cells activation and liver fibrosis. [Cellular and Molecular Life Sciences] Full Article